Chemical and biological study of psychoactive compounds from magic mushroom

Among the secondary metabolites present in magic mushrooms, psilocybin stands out for its ability to induce altered states of consciousness, such as ego-dissolution. Psilocybin exerts its psychotherapeutic effects through its dephosphorylation into psilocin, a serotonin analog, which binds to 5-HT2A receptors. The present work aims to compile the most recent studies on psilocybin to evaluate its therapeutic potential. Studies have established a standard dose of 25 mg for clinical trials. Animal research has shown that a single dose can induce neurogenesis. However, it has not yet been concluded whether it is necessary to experience the psychedelic effect to trigger the neuroplasticity effect. Most studies agree that a single dose facilitates the integration of new ideas and a decrease in the weight of higher-order ideas. The REBUS model, which studies the effect of psychedelics, proposes that this is due to the desynchronization of pyramidal neurons in layer 5 of the cortex. At the subjective level, the integration of new ideas is associated with the recognition and integration of the individual's "shadow". At the cellular level, the psychedelic response is mediated by the formation of a G-protein heterodimer between 5-HT2A and mGlu2 receptors. Further investigation of this mechanism may reveal whether it is possible to achieve a therapeutic effect without the psychedelic experience. Most of the preclinical trials with promising results focus on the use of psilocybin as an alternative treatment for patients with anxiety, depression, Post-Traumatic Stress Disorder (PTSD), and Major Depressive Disorder (MDD).

• Huvudupphovsman: Ortega Vallejo, Samuel Esteban (author)
• Materialtyp: bachelorThesis
• Språk: eng
• Publicerad: 2025
• Ämnen: Psilocibina; Psicodélicos; Potencial terapéutico; Psilocybin; Psychedelics; Therapeutic potentials
• Länkar: http://repositorio.yachaytech.edu.ec/handle/123456789/967